A novel iron (II) preferring dopamine agonist chelator D‐607 significantly suppresses &agr;‐syn‐ and MPTP‐induced toxicities in vivo

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neuropharmacology

• Publication date

  2017-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.neuropharm.2017.05.019PMID 28533164PMCID PMC5542047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.

  2017cited by this paper
• Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.

  2016influential reference
• Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.

  2016influential reference
• Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model

  2016cited by this paper
• Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease

  2016cited by this paper
• Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics

  2016cited by this paper
• The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster.

  2015cited by this paper
• Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.

  2015cited by this paper
• DnaJ-1 and karyopherin α3 suppress degeneration in a new Drosophila model of Spinocerebellar Ataxia Type 6.

  2015cited by this paper
• Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.

  2015cited by this paper
• Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

  2015cited by this paper
• The high‐affinity D2/D3 agonist D512 protects PC12 cells from 6‐OHDA‐induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease

  2014cited by this paper
• Using membrane‐targeted green fluorescent protein to monitor neurotoxic protein‐dependent degeneration of Drosophila eyes

  2014cited by this paper
• Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

  2014cited by this paper
• A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease

  2014cited by this paper
• Ubiquitin-Binding Site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23

  2014cited by this paper
• Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

  2014cited by this paper
• Rifampicin and Parkinson’s disease

  2013cited by this paper
• Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.

  2013cited by this paper
• Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.

  2013cited by this paper
• D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson's disease animal model.

  2013cited by this paper
• Probing mechanisms that underlie human neurodegenerative diseases in Drosophila.

  2012cited by this paper
• Ubiquitin-Specific Protease 25 Functions in Endoplasmic Reticulum-Associated Degradation

  2012cited by this paper
• Iron chelation and neuroprotection in neurodegenerative diseases

  2011cited by this paper
• Novel D3 dopamine receptor‐preferring agonist D‐264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine and lactacystin

  2010cited by this paper
• Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkins

  2010cited by this paper
• INHIBITION OF PROLYL HYDROXYLASE PROTECTS AGAINST MPTP-INDUCED NEUROTOXICITY : MODEL FOR THE POTENTIAL INVOLVEMENT OF THE HYPOXIA-INDUCIBLE FACTOR PATHWAY IN PARKINSON ’ S DISEASE

  2009cited by this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cited by this paper
• Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity

  2009cited by this paper
• Transcranial ultrasound as a risk marker for Parkinson's disease

  2009cited by this paper
• Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology

  2009cited by this paper
• Large-scale chemical dissection of mitochondrial function

  2008cited by this paper
• The Deubiquitinating Enzyme Ataxin-3, a Polyglutamine Disease Protein, Edits Lys63 Linkages in Mixed Linkage Ubiquitin Chains*

  2008cited by this paper
• Metal catalyzed oxidation of alpha-synuclein--a role for oligomerization in pathology?

  2008cited by this paper
• A Rapid Method Combining Golgi and Nissl Staining to Study Neuronal Morphology and Cytoarchitecture

  2008cited by this paper
• Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.

  2007cited by this paper
• Individual dopaminergic neurons show raised iron levels in Parkinson disease

  2007cited by this paper
• Potential sources of increased iron in the substantia nigra of parkinsonian patients.

  2006cited by this paper
• Brain iron metabolism.

  2006cited by this paper
• Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition

  2005cited by this paper
• Rasagiline

  2005cited by this paper
• Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron.

  2005cited by this paper
• Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils.

  2004cited by this paper
• [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

  2004cited by this paper
• Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils

  2004influential reference
• Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.

  2004cited by this paper
• MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease

  2004cited by this paper
• Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.

  2004cited by this paper
• Iron, brain ageing and neurodegenerative disorders

  2004cited by this paper
• Molecular Pathways of Neurodegeneration in Parkinson's Disease

  2003cited by this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cited by this paper
• Human neurodegenerative disease modeling using Drosophila.

  2003cited by this paper
• Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.

  2003cited by this paper
• Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor

  2002cited by this paper
• Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

  2001cited by this paper
• Intracellular Chelation of Iron by Bipyridyl Inhibits DNA Virus Replication

  2001cited by this paper
• The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961.

  2001cited by this paper
• The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

  2000cited by this paper
• The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity

  2000cited by this paper
• Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice.

  2000cited by this paper
• Extracellular toxicity of 6-hydroxydopamine on PC12 cells.

  2000cited by this paper
• The parkinsonian toxin MPTP: action and mechanism

  2000cited by this paper
• Autoxidation and Neurotoxicity of 6‐Hydroxydopamine in the Presence of Some Antioxidants

  2000cited by this paper
• A Drosophila model of Parkinson's disease

  2000cited by this paper
• Etiology and pathogenesis of Parkinson's disease.

  1999cited by this paper
• Prospects for new restorative and neuroprotective treatments in Parkinson's disease

  1999cited by this paper
• The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism.

  1998cited by this paper
• Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

  1998cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells.

  1996influential reference
• Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease

  1995cited by this paper
• Iron Acquired from Transferrin by K562 Cells Is Delivered into a Cytoplasmic Pool of Chelatable Iron(II) (*)

  1995influential reference
• Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives.

  1993cited by this paper
• Novel inhibitors of prolyl 4-hydroxylase.

  1992cited by this paper
• Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

  1992cited by this paper
• Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.

  1991cited by this paper
• Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid

  1990cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Modification of Parkinsonism--chronic treatment with L-dopa.

  1969cited by this paper

• Protection Against Cellular Toxicity from Rotenone Treatment by the Neuroprotective, Novel Multifunctional Antiparkinsonian Drug D-512.

  2026cites this paper
• Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations.

  2025cites this paper
• Biological Characterization of the Anti-ferroptotic Properties of a Novel Anti-Parkinsonian Iron (II) Selective Dopamine Agonist, D-583

  2025influential citation
• Further exploration of N-4 substituents on the piperazine ring of the hybrid template 5/ 7-{[2-(4-Aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol and its analog: development of an exceptionally potent agonist for D2 & D3 receptors

  2024cites this paper
• Novel Piperazine Based Compounds Target Alzheimer's Disease Relevant Amyloid β42 and Tau Derived Peptide AcPHF6, and the Lead Molecule Increases Viability in the Flies Expressing Human Tau Protein.

  2024cites this paper
• Role of Nutraceuticals and Physical Activity in Parkinson's Disease Risk and Lifestyle Management.

  2023cites this paper
• On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson’s Disease

  2023cites this paper
• Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy

  2023cites this paper
• Iron chelation and supplementation: A comparison in the management of inflammatory bowel disease using drosophila.

  2023cites this paper
• Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments.

  2023cites this paper
• D-685 Reverses Motor Deficits and Reduces Accumulation of Human α-Synuclein Protein in Two Different Parkinson's Disease Animal Models.

  2023cites this paper
• Inhibiting Erastin‐Induced Ferroptotic Cell Death by Purine‐Based Chelators

  2022cites this paper
• Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders

  2022cites this paper
• A novel multi-target strategy to attenuate the progression of Parkinson's disease by diamine hybrid AGE/ALE inhibitor.

  2021cites this paper
• Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience

  2021cites this paper
• Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies

  2021influential citation
• Dopamine agonists in treatment of Parkinson's disease: an overview

  2020cites this paper
• Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease

  2020cites this paper
• Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts

  2020cites this paper
• Novel approaches to counter protein aggregation pathology in Parkinson's disease.

  2020cites this paper
• An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease

  2020cites this paper
• Overdosing on iron: Elevated iron and degenerative brain disorders

  2020cites this paper
• Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.

  2020cites this paper
• Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

  2019cites this paper
• The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy.

  2019cites this paper
• Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia

  2019cites this paper
• The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System

  2019cites this paper
• Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia Type 3 disease protein

  2019cites this paper
• Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease.

  2018cites this paper
• Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade.

  2018cites this paper
• Carbazole Based Multifunctional Dopamine Agonists And Related Molecules As Potential Symptomatic And Disease Modifying Therapeutic Agents For Parkinson’s Disease

  2018cites this paper
• Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?

  2018cites this paper
• New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases

  2018cites this paper
• Potentiel thérapeutique de neurones dopaminergiques dérivés de cellules souches embryonnaires de souris dans un modèle murin de la maladie de Parkinson

  2017cites this paper